These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26061438)

  • 21. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.
    Chan MM; Haydu LE; Menzies AM; Azer MW; Klein O; Lyle M; Clements A; Guminski A; Kefford RF; Long GV
    Cancer; 2014 Oct; 120(20):3142-53. PubMed ID: 24985732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming metastatic melanoma with BRAF inhibitors.
    Hong S; Hong S; Han SB
    Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
    Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
    J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
    Ackerman A; Klein O; McDermott DF; Wang W; Ibrahim N; Lawrence DP; Gunturi A; Flaherty KT; Hodi FS; Kefford R; Menzies AM; Atkins MB; Long GV; Sullivan RJ
    Cancer; 2014 Jun; 120(11):1695-701. PubMed ID: 24577748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
    Maxwell R; Garzon-Muvdi T; Lipson EJ; Sharfman WH; Bettegowda C; Redmond KJ; Kleinberg LR; Ye X; Lim M
    Int J Cancer; 2017 Jun; 140(12):2716-2727. PubMed ID: 27342756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.
    Anforth R; Menzies A; Byth K; Carlos G; Chou S; Sharma R; Scolyer RA; Kefford R; Long GV; Fernandez-Peñas P
    J Am Acad Dermatol; 2015 May; 72(5):809-15.e1. PubMed ID: 25748298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Targeted molecular therapies (except immunotherapy)].
    Roux J; Pages C; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
    Kakavand H; Wilmott JS; Menzies AM; Vilain R; Haydu LE; Yearley JH; Thompson JF; Kefford RF; Hersey P; Long GV; Scolyer RA
    Clin Cancer Res; 2015 Jul; 21(14):3140-8. PubMed ID: 25609064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
    Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P
    Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.
    Grimaldi AM; Simeone E; Palla M; Festino L; Caracò C; Mozzillo N; Petrillo A; Muto P; Ascierto PA
    Anticancer Drugs; 2015 Apr; 26(4):464-8. PubMed ID: 25622086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
    Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
    Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
    Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
    Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.
    Schreuer MS; Chevolet IL; Jansen YJ; Seremet TC; Wilgenhof S; Liénard D; Del Marmol V; Neyns B
    Melanoma Res; 2015 Feb; 25(1):68-74. PubMed ID: 25396684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma.
    Carrera C; Puig-Butillè JA; Tell-Marti G; García A; Badenas C; Alós L; Puig S; Malvehy J
    JAMA Dermatol; 2015 May; 151(5):544-8. PubMed ID: 25651238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.